ALMS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AL

Mkt Cap

$790.3M

Volume

1.85M

Next Earnings

November 12th

Loading chart

AL

ALMSAlumis Inc. Common Stock

ALMS

Pay with—

Available Balance0.00

AL

Mkt Cap

$816.7M

Volume

1.85M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterCormorant Asset Management increased its stake in Alumis by 313,645 shares ($7.84 million) in Q1 2026, bringing its position to 4.37% of assets. Alumis shares have surged 400% over the past year, driven by strong Phase 3 psoriasis trial data for its lead drug envudeucitinib. The company has $569.5 million in cash and plans to submit an NDA in Q4 2026, with pivotal lupus data expected in Q3.The Motley Fool · May 17, 2026

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightOver 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.GlobeNewswire Inc. · Apr 14, 2026

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisAlumis announced positive Phase 3 results for envudeucitinib, a TYK2 inhibitor for moderate-to-severe plaque psoriasis. The drug achieved PASI 90 responses in 68.0% and 62.1% of patients by Week 24, with PASI 100 complete clearance in 41.0% and 39.5%. Quality-of-life improvements and itch relief emerged early, with a favorable safety profile. The company plans to submit an NDA to the FDA in the second half of 2026.GlobeNewswire Inc. · Mar 28, 2026

Alumis Announces Pricing of Upsized Public Offering of Common StockAlumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2.65 million shares. Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are serving as joint book-running managers.GlobeNewswire Inc. · Jan 8, 2026

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for EnvudeucitinibAlumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.The Motley Fool · Jan 6, 2026

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque PsoriasisAlumis Inc. announced it will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib for moderate-to-severe plaque psoriasis on January 6, 2026, at 8:00 a.m. ET. The company will host a conference call and webcast to discuss the results.GlobeNewswire Inc. · Jan 5, 2026

Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightOver 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.GlobeNewswire Inc. · Oct 16, 2025

Alumis Misses Q2 Revenue as Costs JumpAlumis reported mixed Q2 2025 results, with missed revenue expectations and high operating expenses due to the ACELYRIN merger. The company completed patient enrollment in key clinical trials for envudeucitinib and maintains sufficient funding through 2027.The Motley Fool · Aug 13, 2025

Alumis Completes Merger with ACELYRINAlumis Inc. has completed its merger with ACELYRIN, Inc. The merger strengthens Alumis' balance sheet and supports the advancement of its late-stage pipeline of targeted therapies for immune-mediated diseases.Benzinga · May 21, 2025

Alumis Stockholders Approve Merger with ACELYRINAlumis Inc. and ACELYRIN, INC. announced that Alumis' stockholders voted to approve the pending merger between the two companies. The merger is expected to close in the second quarter of 2025, subject to customary closing conditions.GlobeNewswire Inc. · May 13, 2025

to start trading

AL

ALMSAlumis Inc. Common Stock

ALMS

Pay with—

Available Balance0.00

Your PositionYou don't own any ALMS yet.

Related Tickers

Earnings